PFE logo
Pfizer Inc.
PFE
26.92 (-1.10%) 0.30
Health Care
Pharmaceuticals
Pfizer Inc. discovers develops manufactures markets distributes and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma PC1 and Pfizer Ignite. The company offers internal medicine products including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family Abrysvo Nimenrix FSME/IMMUN-TicoVac and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products such as Xeljanz Enbrel Cibinqo Litfulo Eucrisa and Velsipity; rare disease products for therapeutic areas comprising amyloidosis hemophilia and endocrine diseases under the Vyndaqel family Genotropin BeneFIX Xyntha Somavert Ngenla and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta Octagam and Panzyga brands. In addition the company offers oncology products comprising ADCs small molecules bispecific and other immunotherapies for the treatment of cancers including breast cancer genitourinary cancer and hematologic malignancies as well as melanoma gastrointestinal gynecological and lung cancer under the Ibrance Xtandi Padcev Adcetris Inlyta Lorbrena Bosulif Tukysa Braftovi Mektovi Orgovyx Elrexfio Tivdak and Talzenna brands. Further it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit Ruxience Zirabev Trazimera and Nivestym and other biosimilars; and sterile injectables such as Sulperazon Atgam Fragmin Solu Medrol Solu Cortef and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US Inc.; Merck KGaA; and BioNTech SE as well as a strategic collaboration with Boltz PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York New York.

Quality Checklist 3/8

Debt/Equity < 1
Current Ratio > 1
Net Margin > 10%
5Y Shares Out Change < 0%
ROIC > 10%
Quick Ratio > 1
Past Net Income CAGR > 0%
Est. EPS Growth > 5%
0.0%of Portfolio

My holdings

Day change:
Total change:
Shares:
Cost basis:
Market cap: $153.13(B)
EV: $214.59(B)
Total Equity: $86.78(B)
Earnings date: May-05-2026
P/E: 19.65
Forward P/E: 9.09
P/FCF: 16.82
P/S: 2.45
P/B: 1.77
EPS: $1.4
EPS (fwd): $3.0
FCF/share: $1.6
Revenue/share: $11.0
Book value/share: $15.2
ROIC: 6.3%
ROA: 4.6%
ROE: 10.6%
Debt/Equity: 0.78
Current Ratio: 1.20
Gross margin: 75.8%
Operating margin: 24.6%
Net margin: 12.4%
Dividend/share: $1.7
Div. yield: 6.39%

Growth Estimates

Revenue

CAGR: -4.2%
FY+1FY+2FY+3FY+4FY+5
FY+1$61.19(B)
FY+2(-3.7%)$58.93(B)
FY+3(-6.6%)$55.05(B)
FY+4(-5.1%)$52.25(B)
FY+5(-1.2%)$51.59(B)

Net Income

CAGR: -7.4%
FY+1FY+2FY+3FY+4FY+5
FY+1$16.91(B)
FY+2(-4.9%)$16.08(B)
FY+3(-12.9%)$14.00(B)
FY+4(-12.6%)$12.24(B)
FY+5(+1.5%)$12.42(B)

EPS

CAGR: -7.5%
FY+1FY+2FY+3FY+4FY+5
FY+1$2.96
FY+2(-4.7%)$2.82
FY+3(-13.8%)$2.43
FY+4(-12.3%)$2.13
FY+5(+1.9%)$2.17

FCF per share

CAGR: -5.7%
FY+1FY+2FY+3FY+4FY+5
FY+1$3.44
FY+2(-6.6%)$3.22
FY+3(-10.7%)$2.87
FY+4(-2.8%)$2.79
FY+5(-2.3%)$2.73